Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Paclitaxel in Advanced Gastric Cancer (KEYNOTE-061)
NCT02370498Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2015
- Primary completion
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free Survival in PD-L1 Positive Participants (BICR) up to 30 months and Overall Survival in PD-L1 Positive Participants up to 30 months. Started May 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02370498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370498.